Abstract WMP114: EZH2 Inhibitor Improves Cognitive Behavior in CAA

Zahid Iqbal,Ahmad El Hamamy,Ngoc Mai Le,Arya Ranjan,Li Qi,Chunfeng Tan,Louise D McCullough,Jun Li
DOI: https://doi.org/10.1161/str.55.suppl_1.wmp114
IF: 10.17
2024-02-01
Stroke
Abstract:Introduction: Cerebral amyloid angiopathy (CAA) is characterized by the deposition of amyloid-β (Aβ) in the leptomeningeal and cortical vessels. CAA may lead to dementia and stroke; however effective options currently are very limited to treat or halt CAA progression. EZH2 (enhancer of zeste 2 polycomb repressive complex 2) is a histone methyltransferase, a key regulator of inflammation and microglia phagocytosis. The present study investigates the therapeutic potential of an EZH2 inhibitor (GSK343) in CAA mice. Methods: Brain samples were collected from a cohort of 4 WT and 4 TgSwDI (CAA model) male mice and lysed for immunoblot analysis to quantify EZH2 and H3K27me3 expression levels. A second cohort of 10 WT and 20 TgSwDI male mice (15 months old) were randomly assigned into DMSO (vehicle) and GSK343 groups. After performing baseline behavioral testing (Barnes maze and NORT), WT and TgSwDI-DMSO groups were injected with 0.1% DMSO while TgSwDI-GSK343 groups were injected with GSK343 (5 mg/kg) every other day intraperitoneally. After 6 weeks of treatment, behavioral testing was performed, and brain tissues were collected for IHC. Data are presented as Mean±SEM. Results: Immunoblot assays showed elevated expression of EZH2 and H3K27me3 in TgSwDI in comparison to WT mice. TgSwDI mice injected with GSK343 had improvements in the ability to recognize a novel object (58.36%±1.84) as compared to TgSwDI controls (45.04%±3.41) in the NORT ( p = 0.0006). The latency to escape (63.08±2.86) was significantly faster in GSK343-treated mice compared to TgSwDI control mice (77.34±3.43) in the Barnes maze ( p = 0.003). IHC results were in line with behavioral testing as GSK343 reduced the expression of EZH2 and Aβ in the hippocampus and frontal cortex. Conclusions: Our study revealed that EZH2 expression is upregulated in the brain of CAA-model mice. Pharmacological inhibition of EZH2 improved cognitive outcomes in CAA mice, suggesting a possible therapeutic target.
peripheral vascular disease,clinical neurology
What problem does this paper attempt to address?